Relationship of coagulation and fibrinolytic variables with arterial structure and function in Africans

Thrombosis Research

Volumn 134, Issue 1, 2014, Pages 78-83

  Pieters, M ^a   Boshuizen, H ^b   De Lange, Z ^a   Schutte, A E ^a   Schutte, R ^a   Greeff, M ^a   Ariens R A S ^c  

^a NORTH WEST UNIVERSITY   (South Africa)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Arterial structure and function; Cardiovascular disease; Disease progression; Fibrin clot lysis time; Fibrinogen

Indexed keywords

FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTERIAL PRESSURE; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE; CARDIOVASCULAR RISK; CAROTID ARTERY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; AFRICA; BLACK PERSON; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; DISEASE COURSE; ETHNOLOGY; METABOLISM; PHYSIOLOGY; RISK FACTOR;

AFRICA; AFRICAN CONTINENTAL ANCESTRY GROUP; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FIBRIN CLOT LYSIS TIME; FIBRINOGEN; FIBRINOLYSIS; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84902548072     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.04.021     Document Type: Article

References (47)

1. R. Ajjan, and P.J. Grant Coagulation and atherothrombotic disease Atherosclerosis 186 2006 240 259
2. J. Danesh, S. Lewington, S.G. Thompson, G.D.O. Lowe, and R. Collins Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis JAMA 294 2005 1799 1809
3. W.B. Kannel Overview of hemostatic factors involved in atherosclerotic cardiovascular disease Lipids 40 2005 1215 1220
4. I. Tzoulaki, G.D. Murray, A.J. Lee, A. Rumley, G.D. Lowe, and F.G. Fowkes Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study Circulation 115 2007 2119 2127
5. P. Willeit, A. Thompson, T. Aspelund, A. Rumley, G. Eiriksdottir, and G. Lowe et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses PLoS One 8 2013 e55175
6. J.G. Van der Bom, M.P. de Maat, M.L. Bots, F. Haverkate, P.T. de Jong, and A. Hofman et al. Elevated plasma fibrinogen: cause or consequence of cardiovascular disease? Arterioscler Thromb Vasc Biol 18 1998 621 625
7. M.G. Hennerici, R. Kay, J. Bogousslavsky, G.L. Lenzi, M. Verstraete, and J.M. Orgogozo Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial Lancet 368 2006 1871 1878
8. A.M. Thogersen, J.H. Jansson, K. Boman, T.K. Nilson, L. Weinehall, and F. Huhtasaari et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor Circulation 98 1998 2241 2247
9. M. Cushman, R.N. Lemaitre, L.H. Kuller, B.M. Psaty, E.M. Macy, and A.R. Sharrett et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study Arterioscler Thromb Vasc Biol 19 1999 493 498
10. L. Johansson, J.H. Jansson, K. Boman, T.K. Nilsson, B. Stegmayr, and G. Hallmans Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke Stroke 31 2000 26 32
11. A.R. Folsom, N. Aleksic, E. Park, V. Salomaa, H. Juneja, and K.K. Wu Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study Arterioscler Thromb Vasc Biol 21 2001 611 617
12. G.D. Lowe, J. Danesh, S. Lewington, M. Walker, L. Lennon, and A. Thomson et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis Eur Heart J 25 2004 252 259
13. I. Tzoulaki, G.D. Murray, A.J. Lee, A. Rumley, G.D. Lowe, and F.G. Fowkes Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study Eur Heart J 28 2007 354 362
14. I. Tzoulaki, G.D. Murray, J.F. Price, F.B. Smith, A.J. Lee, and A. Rumley et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study Am J Epidemiol 163 2006 334 341
15. V. Salomaa, V. Stinson, J.D. Kark, A.R. Folsom, C.E. Davis, and K.K. Wu Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study Circulation 91 1995 284 290
16. Y. Nishiwaki, T. Takebayashi, K. Omae, C. Ishizuka, T. Nomiyama, and H. Sakurai Relationship between the blood coagulation-fibrinolysis system and the subclinical indicators of arteriosclerosis in a healthy male population J Epidemiol 10 2000 34 41
17. A. Luttun, F. Lupu, E. Storkebaum, M.F. Hoylaerts, L. Moons, and J. Crawley et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 22 2002 499 505
18. T.J. Wang, P. Gona, M.G. Larson, D. Levy, E.J. Benjamin, and G.H. Tofler et al. Multiple biomarkers and the risk of incident hypertension Hypertension 49 2007 432 438
19. W. Lieb, M.G. Larson, E.J. Benjamin, X. Yin, G.H. Tofler, and J. Selhub et al. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study Circulation 119 2009 37 43
20. L. Traby, M. Kollars, L. Eischer, S. Eichinger, and P.A. Kyrle Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study PLoS One 7 2012 e51447
21. T.W. Meade, J.A. Cooper, R. Chakrabarti, G.J. Miller, Y. Stirling, and D.J. Howarth Fibrinolytic activity and clotting factors in ischaemic heart disease in women BMJ 312 1996 1581
22. T.W. Meade, V. Ruddock, Y. Stirling, R. Chakrabarti, and G.J. Miller Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study Lancet 342 1993 1076 1079
23. S. Uitte de Willige, K.F. Standeven, H. Philippou, and R.A. Ariens The pleiotropic role of the fibrinogen gamma' chain in hemostasis Blood 114 2009 3994 4001
24. K. Teo, C.K. Chow, M. Vaz, S. Rangarajan, and S. Yusuf The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries Am Heart J 158 2009 1 7
25. S. Yusuf, S. Islam, C.K. Chow, S. Rangarajan, G. Dagenais, and R. Diaz et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey Lancet 378 2011 1231 1243
26. S. Uitte de Willige, M.C. de Visser, J.J. Houwing-Duistermaat, F.R. Rosendaal, H.L. Vos, and R.M. Bertina Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels Blood 106 2005 4176 4183
27. M. Pieters, R.C. Kotze, J.C. Jerling, A. Kruger, and R.A. Ariens Evidence that fibrinogen gamma' regulates plasma clot structure and lysis and relationship to cardiovascular risk factors in black Africans Blood 121 2013 3254 3260
28. T. Lisman, P.G. de Groot, J.C. Meijers, and F.R. Rosendaal Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis Blood 105 2005 1102 1105
29. C. Duckers, P. Simioni, L. Spiezia, C. Radu, P. Dabrilli, and S. Gavasso et al. Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms Blood 115 2010 879 886
30. M. Pieters, M.P. de Maat, J.C. Jerling, T. Hoekstra, and A. Kruger Fibrinogen concentration and its role in CVD risk in black South Africans-effect of urbanisation Thromb Haemost 106 2011 448 456
31. Z. De Lange, M. Pieters, J.C. Jerling, A. Kruger, and D.C. Rijken Plasma clot lysis time and its association with cardiovascular risk factors in black Africans PLoS One 7 2012 e48881
32. M. Pieters, and H.H. Vorster Nutrition and hemostasis: a focus on urbanization in South Africa Mol Nutr Food Res 52 2008 164 172
33. S. Kaptoge, I.R. White, S.G. Thompson, A.M. Wood, S. Lewington, and G.D.O. Lowe et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration Am J Epidemiol 166 2007 867 879
34. A.R. Folsom, K.K. Wu, M.G. Conlan, A. Finch, C.E. Davis, and G. Marcucci et al. Distributions of hemostatic variables in blacks and whites: population reference values from the Atherosclerosis Risk in Communities (ARIC) Study Ethn Dis 2 1992 35 46
35. D. Lominadze, W.L. Dean, S.C. Tyagi, and A.M. Roberts Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease Acta Physiol (Oxf) 198 2010 1 13
36. P. de Moerloose, F. Boehlen, and M. Neerman-Arbez Fibrinogen and the risk of thrombosis Semin Thromb Hemost 36 2010 7 17
37. U. Wall, C. Jern, A. Bergbrant, and S. Jern Enhanced levels of tissue-type plasminogen activator in borderline hypertension Hypertension 26 1995 796 800
38. K.A. Poli, G.H. Tofler, M.G. Larson, J.C. Evans, P.A. Sutherland, and I. Lipinska et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population Circulation 101 2000 264 269
39. G.Y. Lip, and A.D. Blann Does hypertension confer a prothrombotic state? Virchow's triad revisited Circulation 101 2000 218 220
40. K. Kaikita, A.B. Fogo, L. Ma, J.A. Schoenhard, N.J. Brown, and D.E. Vaughan Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition Circulation 104 2001 839 844
41. H.D. Intengan, and E.L. Schiffrin Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis Hypertension 38 2001 581 587
42. V. Salomaa, V. Stinson, J.D. Kark, A.R. Folsom, C.E. Davis, and K.K. Wu Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study Circulation 91 1995 284 290
43. H. Tomiyama, Y. Kimura, H. Mitsuhashi, T. Kinouchi, H. Yoshida, and T. Kushiro et al. Relationship between endothelial function and fibrinolysis in early hypertension Hypertension 31 1998 321 327
44. P.M. Ridker, C.H. Hennekens, M.J. Stampfer, J.E. Manson, and D.E. Vaughan Prospective study of endogenous tissue plasminogen activator and risk of stroke Lancet 343 1994 940 943
45. A. Mbewu, and J.C. Mbanya Cardiovascular Disease 2006
46. M.D. Connor, G. Modi, and C.P. Warlow Differences in the nature of stroke in a multiethnic urban South African population: the Johannesburg hospital stroke register Stroke 40 2009 355 362
47. B. Siegerink, M.E. Meltzer, P.G. De Groot, A. Algra, T. Lisman, and F.R. Rosendaal Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study Br J Haematol 156 2012 252 258